0
Deep & Emerging Tech·August 5, 2026·1 min read

Goldman-Backed Biotech Attovia Raises $289 Million in US IPO

Share

A $289M IPO for an early-stage immune-disease biotech is another data point that public markets will still fund long-horizon, high-science platforms. For AI-first drug discovery and tooling startups, this is a reminder that the exit path may be via enabling these platforms, not replacing them.